Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is a standard treatment for relapsed or refractory B-cell non-Hodgkin lymphomas. Long-term results and curative potential remain uncertain. We ...
Researchers have created one of the most detailed maps to date of how white blood cells called B cells develop and behave ...
Chennai, Aug. 28 -- Highlights: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results